(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 3.43% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Ginkgo Bioworks Holdings's revenue in 2025 is $227,043,000.On average, 2 Wall Street analysts forecast DNA's revenue for 2025 to be $9,951,833,862, with the lowest DNA revenue forecast at $9,921,946,558, and the highest DNA revenue forecast at $9,981,779,200. On average, 2 Wall Street analysts forecast DNA's revenue for 2026 to be $11,349,921,320, with the lowest DNA revenue forecast at $10,910,316,800, and the highest DNA revenue forecast at $11,789,525,840.
In 2027, DNA is forecast to generate $15,313,151,931 in revenue, with the lowest revenue forecast at $15,313,151,931 and the highest revenue forecast at $15,313,151,931.